A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

DRUG: Tarlatamab
DRUG: AB248

Sponsor

Amgen

Collaborators

[object Object]